Challenges facing antiangiogenic therapy for cancer: Impact of the tumor extracellular environment

Expert Review of Anticancer Therapy

Volumn 4, Issue 1, 2004, Pages 129-140

  Gagne, Paul ^a   Akalu, Abebe ^a   Brooks, Peter C ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Clinical trials; Drug resistance; Extracellular matrix; Growth factors; Integrins; Protease; Tumor growth

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; CYTOSTATIC AGENT; CYTOTOXIC AGENT; DOXORUBICIN; ENDOSTATIN; FIBRINOGEN; FIBRONECTIN; FUMAGILLOL CHLOROACETYLCARBAMATE; LAMININ; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HUI77; MONOCLONAL ANTIBODY HUIV25; NANOPARTICLE; OSTEOPONTIN; PERLECAN; RESTIN; RETINA S ANTIGEN; THROMBOSPONDIN; THROMBOSPONDIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VIRUS VECTOR;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESEARCH; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG MONITORING; DRUG POTENTIATION; DRUG SYNTHESIS; DRUG TARGETING; EXPERIMENTAL DESIGN; EXTRACELLULAR MATRIX; EXTRACELLULAR SPACE; GENE THERAPY; HUMAN; IN VIVO STUDY; IONIZING RADIATION; MALIGNANT NEOPLASTIC DISEASE; MENSTRUATION DISORDER; MICROENVIRONMENT; NONHUMAN; PREGNANCY DISORDER; REGULATORY MECHANISM; REVIEW; RNA INTERFERENCE; SIDE EFFECT; TISSUE PERFUSION; TUMOR GROWTH; TUMOR RESISTANCE;

EID: 1142275206     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.4.1.129     Document Type: Review

References (78)

1. Noden DM. Embryonic origins and assembly of blood vessels. Ann. Rev. Respir. Dis. 140, 1097-1103 (1989).
2. Risau W. Mechanisms of angiogenesis. Nature 368, 671-674 (1997).
3. Scholz D, Cai WJ, Schaper W. Arteriogenesis, a new concept of vascular adaptation in occlusive disease. Angiogenesis 4, 247-257 (2001).
4. Folkman J. Tumor angiogenesis: therapeutic implication. N. Engl. J. Med. 285, 1182-1186 (1971).
5. Flamme I, Frolich T, Risua W. Molecular mechanisms of vasculogenesis and embryonic angiogenesis. J. Cell. Physiol. 172, 206-210 (1997).
6. Stouffer RL, Martinez-Chequer JC, Molskness TA et al. Regulation and action of angiogenic factors in the primate ovary. Arch. Med. Res. 32, 567-575 (2001).
7. Mattioli M, Barboni B, Urtiani M et al. Follicle activation involves vascular endothelial growth factor production and increased blood vessel extension. Biol. Reprod. 65, 1014-1019 (2001).
8. Friedlander M, Thesefeld CL, Sugita M et al. Involvement of integrin αvβ3 and αvβ5 in ocular neovascular diseases. Proc. Natl Acad. Sci. USA 93, 9764-9769 (1996).
9. Paleolog EM, Miotia JM. Angiogenesis in arthritis: role in disease pathogenesis and as a potential therapeutic target. Angiogenesis 2, 295-307 (1999).
10. Creamer D, Sullivan D, Bicknell R, Barker J. Angiogenesis in psoriasis. Angiogenesis 5, 231-236 (2002).
11. Rodriguez D, Brooks PC. Integrin receptors and the regulation of angiogenesis. In: The New Angiotherapy. Fan T-PD, Kohn E (Eds), Humana Press, Inc., NJ, USA, 67-79 (2002).
12. Norrby K. Mast cells and angiogenesis. APMIS 110, 355-371 (2002).
13. Xu J, Brooks PC. Extracellular matrix in the regulation of angiogenesis. Assembly of the vasculature and its regulation. Birkhauser 67-95 (2002).
14. Brooks PC. Co-operative integrin interactions in the regulation of tumor metastasis. In: Cancer Metastasis Related Genes. Kluwer Acadademic Press, MA, USA, 65-87 (2002).
15. Felmeden DC, Blann AD, Lip GYH. Angiogenesis: basic pathophysiology and implications for disease. Eur. Heart. J. 1, 1-19 (2003).
16. Folkman J, Klagsburn M. Angiogenic factors. Science 235, 442-447 (1987).
17. Eliceiri B. Integrin and growth factor receptor crosstalk. Cir. Res. 89, 1104-1110 (2001).
18. Sellke FW, Ruel M. Vascular growth factors and angiogenesis in cardiac surgery. Ann. Thorac. Sur. 75, S685-S690 (2003).
19. Xu J, Rodriguez D, Kim JJ et al. Generation of monoclonal antibodies to cryptic collagen sites by using subtractive immunization. Hybridoma 19, 375-385 (2000).
20. Xu J, Rodriguez D, Petitclerc P et al. Proteolytic exposure of a cryptic site within collagen type-IV is required for angiogenesis and tumor growth in vivo. J. Cell Biol. 1154, 1069-1079 (2001).
21. Hangai M, Kitaya N, Xu J et al. Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis. Am. J. Pathol. 161, 1429-1437 (2002).
22. Petitclerc P, Stromblad S, von Schalscha TL et al. Integrin αvβ3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res. 59, 2724-2730 (1999).
23. Davis GE, Bayless KJ. An integrin and Rho GTase-dependent pinocytotic vacuole mechanism controls capillary lumen formation in collagen and fibrin matrices. Microcirculation 10, 27-44 (2003).
24. Rafii S, Lyden D, Benezar R et al. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy. Nature Rev. Cancer 2, 826-835 (2002).
25. Adras SS, Paul T, Bertoncini J et al. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am. J. Pathol. 162, 1951-1960 (2003).
26. Holash J, Maisonpierre PC, Compton D et al. Vessel cooption, regression and growth in tumors mediated by angiopoiteins and VEGF. Science 284, 1994-1998 (1999).
27. Maniotis AJ, Folberg R, Hess A et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am. J. Pathol. 155, 739-752 (1999).
28. Shirakwa K, Kobayashi H, Heike Y et al. Hemodynamics in vascular mimicry and angiogenesis of inflammatory breast cancer xenografts. Cancer Res. 62, 560-566 (2002).
29. Chang YS, DiTomaso E, McDonald DM et al. Mosaic blood vessels in tumors: frequency in cancer cells in contact with flowing blood. Proc. Natl Acad. Sci. USA 97, 14608-14613 (2000).
30. Rybak SM, Sanovich E, Hollingshead MG et al. Vasocrine formation of tumor cell lined vascular spaces: implications for rational design of antiangiogenic therapies. Cancer Res. 63, 2812-2819 (2003).
31. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nature Rev. Cancer. 2, 727-739 (2002).
32. Folkman J. Angiogenesis and apoptosis Semin. Cancer Biol. 13, 159-167 (2003).
33. Arap W, Kolonin MG,Trepel M et al. Steps toward mapping the human vasculature by phage display. Nature Med. 8, 121-127 (2002).
34. St Croix B, Rago C, Velculescu V et al. Genes expressed in human tumor endothelium. Science 89, 1197-1202 (2000).
35. Ozaki H, Okamoto N, Ortega S et al. Basic fibroblast growth factor is neither necessary nor sufficient for the development of retinal neovascularization. Am. J. Pathol. 153, 757-765 (1998).
36. Tobe T, Ortega S, Luna JD et al. Targeted disruption of the FGF-2 gene does not prevent chorodial neovascutarization in a murine model. Am. J. Pathol. 153, 1641-1645 (1998).
37. Friedlander M, Brooks PC, Shaffer RW et al. Definition of two angiogenic pathways by distinct αv integrins. Science 270, 1500-1502 (1995).
38. Alavi A, Hood JD, Frausto R et al. Role of Raf in vascular protection from distinct apoptotic stimuli. Science 301, 94-96 (2003).
39. Reif M, LeJeune S, Scottt PA et al. Expression of the angiogenic factors vascular endothelial cell growth factors, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 57, 963-969 (1997).
40. Bergers G, Song S, Meyer-Morse N et al. Benefits of targeting both pericytes and endothelial cells in tumor vasculature with kinase inhibitors. J. Clin. Invest. 111, 1287-1295 (2003).
41. Bergers G, Hanahan D. Combining anti-angiogenic agents with metronomic chemotherapy enhances efficacy against late stage pancreatic islet carcinomas in mice. Cold Spring Harb. Symp. Quant. Biol, 678, 293-300 (2003).
42. Bergers G, Brekken R, McMahon G et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biol. 2, 737-744. (2000).
43. Stadler WM, Kuzel T, Shapiro C et al. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J. Clin. Oncol. 17, 2541-2545 (1999).
44. Reinmuth N, Liu W, Jung YD et al. Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB J. 15, 1239-1241 (2001).
45. Brooks PC, Stromblad S, Sanders LC et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αvβ3. Cell 85, 683-693 (1996).
46. Seo DW, Li H, Guedez L et al. TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 114, 171-180 (2003).
47. Munger JS, Huang X, Kawakatsu H et al. The integrin αvβ6 binds and activates latent TGF β1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96, 319-328 (1999).
48. Brooks PC. Role of integrins in angiogenesis. Eur. J. Cancer 32A, 2423-2329 (1996).
49. Hynes RO. Integrins: versatility, modulation and signaling in cell adhesion. Cell 60, 11-25 (1992).
50. Brooks PC, Clark RAF, Cheresh DA. Requirement of vascular integrin αvβ3 for angiogenesis. Science 264, 569-571 (1994).
51. De Arcangelis A, Mork M, Keidberg J et al. Synergestic activities of α3 and α6 integrins are required during apical ectodermal ridge formation and organogenesis in the mouse. Development 126, 3957-3968 (1999).
52. Gustafasson E, Fassler R. Insight into extracellular matrix functions from mutant mouse models. Exp. Cell Res. 261, 52-68 (2000).
53. Bader BL, Rayburn H, Crowley D et al. Extensive vasculogenesis, angiogenesis and organogenesis precedes lethality in mice lacking all αv integrins. Cell 95, 507-519 (1998).
54. Lewis JM, Tmong TN, Schwartz MA. Integrins regulate the apoptotic response to DNA damage through modulation of p53. Proc. Natl Acad. Sci. USA 99, 3627-3632 (2002).
55. Brooks PC, Montgomery AMP, Rosenfeld M et al. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenesis blood vessels. Cell 79, 1157-1164 (1994).
56. Stupack DG, Puente XS, Boutsaboualoy S et al. Apoptosis of adherent cells by recruitment of caspase 8 to unligated integrins. J. Cell Biol, 155, 459-470 (2001).
57. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J. Cell. Physiol. 115, 3719-3727 (2001).
58. Qi JH, Ebrahem Q, Moore N et al. A novel function for tissue inhibitor of metalloproteinase-3 (TIMP-3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nature Med. 9, 407-415 (2003).
59. Davis DW, McConkey DJ, Abbruzzes JL, Herbst RS. Surrogate markers in anti-angiogenesis clinical trials. Br. J. Cancer 89, 8-14 (2003).
60. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of anti-angiogenic therapy: microvessel density, what it dose and doesn't tell us. J. Natl Cancer. Inst. 94, 883-893 (2002).
61. Anderson H, Price P, Blomely M et al. Measuring changes in human tumor vasculature in response to therapy using functional imaging techniques. Br. J. Cancer 85, 1085-1093 (2001).
62. Scappaticci FA. The therapeutic potential of novel anti-angiogenic therapies. Expert Opin. Investig. Drugs 12, 923-932 (2003).
63. McCarty MF, Liu W, Fan F et al. Promises and pitfalls of anti-angiogenic therapy in clinical trials. Trends Mol. Med. 9, 53-58 (2003).
64. Vousden KH, Lu Y, Live or let die: the cells response to p53. Nature Rev. Cancer 2, 594-604 (2002).
65. Stromblad S, Fotedar A, Brickneer H et al. Loss of p53 compensates for αv-integrin function in retinal neovascularization. J. Biol. Chem. 277, 13371-13374 (2002).
66. Teicher BA, Dupuis N, Kusomoto T et al. Anti-angiogenic agents can increase tumor oxygenation and response to radiation therapy Radiat. Oncol. Invest. 2, 269-276 (2001).
67. Herbst RS, Mullani NA, Davis DW et al. Development of biologic markers of response and assessment of anti-angiogenic activity in a clinical trial of human recombinant endostatin. J. Clin. Oncol. 20, 3804-3814 (2002).
68. Pan Q, Bao LW, Kleer CG et al. Anti-angiogenic tetrathiomlydate enhances the efficacy of doxorubicin against breast carcinoma. Mol. Cancer Ther. 2, 617-622 (2003).
69. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 21, 60-65 (2003).
70. Hood JD, Bednarski M, Frausto R et al. Tumor regression by targeted gene delivery to the neovasculature. Science 296, 2404-2407 (2002).
71. Zhang L, Yang N, Mohamed-Hadley A et al. Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer. Biochem. Biophys. Res. Commun. 303, 1169-1178 (2003).
72. Kyriakides TR, Hartzel H, Huynh G et al. Regulation of angiogenesis and matrix remodeling by localized, matrix-mediated antisense gene delivery. Mol. Ther. 3, 842-849 (2001).
73. Brooks PC, Roth JM, Lymberis SC et al. Ionizing radiation modulates the exposure of the HUIV26 cryptic epitope within collagen type-IV during angiogenesis. Int. J. Radiat. Oncol. Biol. Phys. 54, 1194-1201 (2002).
74. Garcia-Barros M, Paris F, Cordon-Cardo C et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300, 1155-1158 (2003).
75. Kalluri R. Basement membranes: structure, assembly and role in tumor angiogenesis. Nature Rev. Cancer 3, 422-433 (2003).
76. Carnemolla B, Borsi L, Balza E et al. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 99, 159-165 (2002).
77. Sakharov DV, Jie AM, Bekkers MEA et al. Polylysine as a vehicle for extracellular matrix-targeted local drug delivery, providing high accumulation and long-term retention within the vascular wall. Arterioscler. Thromb. Vasc. Biol. 21, 943-948 (2001).
78. Nakashima J, Sumitomo M, Miyajima A et al. The value of serum carboxyterminal propeptide of type-I procollagen in predicting bone metastases in prostate cancer. J. Urol. 157, 1736-1739 (1997).